Evidence map›Paper›PMID 35188985›Full record

ArticleImmunology and cell biology2022

The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.

Preethi Eldi, Tamara H Cooper, Natalie A Prow, Liang Liu, Gary K Heinemann, Voueleng J Zhang, Abigail D Trinidad, Ruth Marian Guzman-Genuino, Peter Wulff, Leanne M Hobbs and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunology and cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Preethi EldiExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
Tamara H CooperExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
Natalie A ProwExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
Liang LiuExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
Gary K HeinemannExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
Voueleng J ZhangExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
Abigail D TrinidadExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
Ruth Marian Guzman-GenuinoSementis Limited, Hackney, SA, Australia.
Peter WulffSementis Limited, Hackney, SA, Australia.
Leanne M HobbsExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
Kerrilyn R DienerExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
John D HayballExperimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia.
SA Health · AUUniversity of South Australia · AULondon Borough of Hackney · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus-based, replication-defective Sementis Copenhagen Vector (SCV) was used to develop a first-generation COVID-19 vaccine encoding the spike glycoprotein (SCV-S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper-biased, spike-specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle-aged mice, with durable immune memory evident even in the presence of pre-existing vector immunity. Therefore, SCV-S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second-generation SCV-based COVID-19 vaccine candidates incorporating additional SARS-CoV-2 immunogens.

Indexed as

COVID-19VacciniaAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansImmunity, CellularImmunity, HumoralMiceSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibodiescellular responsesCOVID-19polyfunctional T cellsSARS-CoV-2spikevaccine

Identifiers

PMID35188985
PMCPMC9111635
OpenAlexW4213370353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.